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Leiomyosarcoma represents about 24% of all soft tissue sarcomas and can originate from retroperitoneum, 
uterus, or extremities. Adequate local control may be achieved with surgery and radiotherapy. In the presence 
of unresectable metastases either doxorubicin- or gemcitabine-based chemotherapy are the standard of treat-
ment. Nevertheless, prognosis remains poor regardless of the selected chemotherapy regimen, and new effec-
tive therapeutic agents for patients with advanced leiomyosarcoma are needed. Trabectedin, a promising new 
DNA-damaging agent with a mechanism of action that is different from that of traditional alkylating agents, is 
approved in Europe for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracy-
clines and ifosfamide, or who are unsuited to receive these agents and in combination with pegylated liposomal 
doxorubicin (PLD) for the treatment of patients with relapsed platinum-sensitive ovarian cancer. We present 
a case of a 76-year-old patient with progressive metastatic lung lesions from a previously resected primary 
leiomyosarcoma of the thigh and moderate renal failure, who achieved 17 months of disease stability during 
third-line treatment with trabectedin. Trabectedin was not associated with any cumulative toxicity and was con-
sistently well tolerated for a total of 22 treatment cycles. Current evidence on trabectedin is also presented.
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Research and Treatment of Cancer, Soft Tissue, and Bone 
Sarcoma Group studies, leiomyosarcomas appeared to 
have poorer response rates to anthracyclines than other 
histological subtypes of soft tissue sarcoma (6), but these 
studies were performed before it was realized that most gas-
trointestinal leiomyosarcomas are actually chemoresistant 
gastrointestinal stromal tumors (5). In general, responses 
to standard first-line anthracycline-based chemotherapy 
are short-lived. Single-agent gemcitabine has shown lim-
ited activity in soft tissue sarcoma in general, with the 
exception of leiomyosarcoma and liposarcoma (5). As 
a second-line strategy, gemcitabine with docetaxel may 
only achieve 32% of best overall response with a median 
progression-free survival of 6.2 months (7).
Earlier this year, the US FDA and European Medicines 
Agency approved the multitargeted angiogenesis inhibi-
tor pazopanib for the treatment of advanced soft tissue 
sarcoma in patients who have received prior chemo-
therapy based on the results of the randomized, placebo-
controlled, phase III PALETTE trial (8). However, the 
INTRODUCTION
Leiomyosarcoma is one of the most frequent sub-
types of soft tissue sarcoma, a rare group of pathologi-
cally heterogeneous tumors of mesenchymal origin (1). 
Leiomyosarcoma can occur anywhere in the body but is 
best known as a tumor occurring in the uterus, retroperi-
toneal space, and nonvisceral soft tissue (2,3). Although 
adequate local control may be achieved with surgery and 
radiotherapy, the long-term prognosis for patients with 
nonvisceral soft tissue leiomyosarcoma is poor (3). The 
site of the primary tumor is an important prognostic fac-
tor, and differences in response to chemotherapy are seen 
for leiomyosarcomas from different anatomical sites, 
with uterine leiomyosarcoma being relatively responsive 
to chemotherapy, and extremity leiomyosarcomas dem-
onstrating low-to-moderate chemosensitivity (4,5).
Anthracycline-based chemotherapy has been standard 
treatment for soft tissue sarcoma since the mid-1970s (5). 
Although not statistically significant, in a review of over 























































2 GALIZIA ET AL.
efficacy of this molecule for the treatment of patients with 
adipocytic STS or gastrointestinal stromal tumors (GIST) 
has not been demonstrated to date. Moreover, a number 
of novel agents are under investigation for the treat-
ment of soft tissue sarcoma, including the microtubule 
inhibitor eribulin, agents targeting mammalian target of 
rapamycin, or insulin-like growth factor receptor. Other 
approaches, as multitargeted tyrosine kinase inhibitors, 
including sorafenib and sunitinib, failed to obtain satisfy-
ing results to date. 
In 2007, trabectedin was approved in Europe for the 
treatment of patients with advanced soft tissue sarcoma 
after failure of anthracyclines and ifosfamide or who are 
unsuited to receive these agents.
Trabectedin, a tetrahydroisoquinoline alkaloid isolated 
from the Caribbean marine tunicate Ecteinascidia turbinata 
and now produced synthetically, has been shown active 
in soft tissue sarcomas (5,9). Trabectedin has a unique 
mechanism of action that involves binding to the minor 
DNA groove and subsequent bending of DNA toward the 
major groove, thereby interfering with DNA repair and 
transcription processes, resulting in cell cycle perturba- 
tions and cell death (10).
We present a case of a patient with metastatic lung 
lesions from a primary leiomyosarcoma of the thigh and 
moderate renal failure who had prolonged stabilization of 
disease during third-line treatment with trabectedin. The 
feasibility of trabectedin treatment in patients with renal 
impairment has been poorly investigated. While a recent 
case report examined trabectedin pharmacokinetics in a 
patient on hemodialysis (11), to our knowledge the effec-
tiveness and safety of trabectedin has not been investi-
gated in patients with moderate renal failure. We also 
present a summary of current evidence on trabectedin.
CASE REPORT
In January 2002, a 69-year-old male was admitted to 
our hospital with a palpable mass in the right thigh. His 
medical history included type 2 diabetes mellitus treated 
with repaglinide, arterial hypertension treated with amlo-
dipine, dyslipidemia treated with pravastatin, and benign 
prostatic hypertrophy treated with tamsulosin and finas-
teride. With the exception of blood glucose levels, blood 
count and biochemistry parameters were normal. Magnetic 
resonance imaging of the right thigh showed a lateral spin-
dle cell mass that was 7 cm in diameter. Computed tomog-
raphy (CT) scan of the chest showed no lung metastases. 
The right thigh mass was successfully resected with wide 
margins. The pathological report was consistent with a 
high-grade pleomorphic sarcoma and a histological diag-
nosis of leiomyosarcoma. Four cycles of intravenous adju-
vant chemotherapy with epirubicin (60 mg/m2 on days 1 
and 2) and ifosfamide (3 g/m2 on days 1–3) repeated every 
21 days, and radiotherapy (66 Gy total) were administered. 
Toxicity was as expected: grade 2 mucositis and grades 
3–4 neutropenia, anemia, and thrombocytopenia. 
The patient was well until February 2007, when a 
follow-up CT scan revealed a 6-mm node in the superior 
lobe of the left lung. Fluorodeoxyglucose-positron emis-
sion tomography (FDG-PET) scan confirmed the presence 
of an isolated lesion in the left lung with increased meta-
bolic activity. In March 2007, resection of this node was 
performed, with histological confirmation of leiomyosar-
coma. Six months later, three new lung nodules, the larg-
est of which was 1.4 cm in diameter, were detected by a 
CT scan. The patient refused surgery and specified that he 
wished to avoid chemotherapy that would cause alopecia 
and mucositis. Gemcitabine (1 g/m2) on days 1, 8, and 15 
repeated every 3 weeks was started, and after two cycles, 
CT scan demonstrated stable disease. A total of eight cycles 
of gemcitabine were administered, with a best response of 
stable disease. The main gemcitabine-associated toxicities 
were grade 2 fatigue, grade 2 thrombocytopenia, and fever. 
After the last cycle of gemcitabine in October 2008, the 
patient asked for a rest period, and a new follow-up phase 
started. 
In March 2009, CT scan showed numeric and dimen-
sional progression of metastatic lung disease, accord-
ing to RECIST criteria (12), with the largest nodule now 
3 cm in diameter. In the meantime, patient’s renal function 
gradually worsened, reaching a nadir creatinine clearance 
of 45 ml/min, calculated with Cockroft-Gault formula. We 
believe this mild renal insufficiency development was due 
to hypertensive plus diabetic nephropathy. Even if 1 L of 
saline solution plus acetilcysteine were administered before 
and after each CT scan, surely a role in kidney function 
worsening was played by iodine contrast medium use. 
Second line treatment with trabectedin (1.3 mg/m2/ 
24 h infusion through a central venous line every 21 days) 
was begun, with dexamethasone 8 mg administered the 
day before and tapered in 4 days after each administration 
of trabectedin. The patient received a total of 22 cycles of 
trabectedin without experiencing any toxicities other than 
grade 1 leucopenia, grade 1 increases in aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) 
levels, and grade 2 fatigue, so no dose adjustment was 
required. Renal function remained stable, and hyperten-
sion was well controlled. Echocardiography, which was 
performed every 6 months, did not reveal any clinically 
relevant abnormalities requiring dose modification. Our 
patient did not report any respiratory symptoms, such 
as cough or dyspnea. During trabectedin treatment, CT 
scans, which were performed every 90 days, recorded no 
progression over 17 months (Fig. 1). In December 2010, 
on the basis of the patient’s own decision, treatment was 
interrupted. At the last follow-up visit, in July 2011, the 
patient was alive and felt well, and according to RECIST 
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TRABECTEDIN: CURRENT EVIDENCE
Pharmacology of Trabectedin
Although the mechanism of action of trabectedin is 
not fully understood, it has been studied in several pre-
clinical in vitro and in vivo models and according to 
recent evidence can be considered as a new multitarget 
chemotherapeutic agent. In contrast to traditional alkylat-
ing agents, which bind guanine at the N7 or O6 position 
in the DNA major groove, trabectedin binds to the N2 
amino group of guanines in the minor DNA groove, caus-
ing several antitumor effects at the transcriptional level 
(10). Trabectedin causes DNA structural modifications 
that may interfere with the recognition of specific DNA 
consensus sequences by some transcription factors, with 
in vitro studies showing that it affects transcription of 
activated genes, and does not seem to affect constitutive 
transcription (10). It is well known that trabectedin affects 
the tumor microenvironment. Indeed, when administrated 
at noncytotoxic concentrations, trabectedin inhibited 
the production by myxoid liposarcoma cells of various 
cytokines and chemokines involved in tumor growth and 
progression (13). Modulation of cytokines and chemo-
kines occurs at the transcriptional level, indicating that 
the drug is active not only in cancer cells but also in some 
normal cells, such as macrophages or endothelial cells, 
which produce factors that are relevant for tumor growth 
and progression (10). Trabectedin-induced DNA damage 
is recognized by nucleotide excision repair (NER) path-
ways, resulting in inhibition of DNA repair proteins and 
induction of cell death. Therefore, in contrast to what 
would be expected from a traditional DNA-damaging 
agent, sensitivity to trabectedin is strictly correlated with 
NER functionality (10,14). When NER does not work 
properly, for example, in xeroderma pigmentosum group 
G gene (XPG) mutations and/or certain excision repair 
cross complementing group 1 gene (ERCC1) polymor-
phisms, trabectedin cytotoxicity is expected to be low. In 
addition, trabectedin induces DNA double strand breaks 
that are repaired by the homologous recombination repair 
(HRR) pathway (10,14). When there is low expression 
or inactivating mutations of HRR machinery, such as the 
breast cancer susceptibility 1 gene (BRCA1), trabectedin 
cytotoxicity is expected to be high. 
Consistent with laboratory models, a retrospective 
study has shown that a composite DNA repair profile 
was predictive of response in patients with advanced sar-
coma treated with trabectedin, whereby low BRCA1 and 
high ERCC1 and/or XPG expression was correlated with 
higher probability of response (14). The molecular char-
acterization of soft tissue sarcomas with respect to their 
DNA repair machinery may have a clinically important 
impact on the individualization of treatment strategies 
(14). For example, loss of BRCA1 expression is known 
to occur in a subset of patients with uterine leiomyosar-
coma (15), so it is possible that these patients may be 
Figure 1. Chest CT scan before (A) and after 3 (B), 12 (C), and 22 (D) cycles of trabectedin. 























































4 GALIZIA ET AL.
particularly responsive to trabectedin. There have been no 
prospective studies of trabectedin in a selected population 
of patients with uterine leiomyosarcoma, but a recent ret-
rospective analysis of 66 patients with advanced uterine 
leiomyosarcoma confirmed that trabectedin was active 
in a subgroup of heavily pretreated patients (objective 
RECIST response rate of 16% and stable disease in 35% 
of patients) (16). In a recent phase II study of trabectedin, 
in 20 patients with previously untreated advanced uter-
ine leiomyosarcoma, there was a 10% partial response 
rate, but more than 50% of patients remained progression 
free and without treatment-ending toxicity for more than 
6 months (10 cycles) (17). It is hoped that, in the future, 
it will be possible to identify subgroups of patients with 
leiomyosarcoma who are likely to do well on trabectedin 
on the basis of biomarkers such as BRCA1. This result 
is currently being studied prospectively in either BRCA 
mutated breast tumors or hereditary ovarian tumors and 
in patients with BRCAness phenotype (MITO 15 study; 
NCT00326456).
Clinical Studies of Trabectedin as Second-Line or 
Salvage Therapy 
The pivotal study of trabectedin is a large open-label 
phase II study as second-line or salvage therapy in 270 
patients with advanced or metastatic soft-tissue sar-
coma (18). They were included in the study if they had 
advanced or metastatic leiomyosarcoma or liposar-
coma with disease progression after at least one cycle of 
anthracycline- and ifosfamide-based chemotherapy. The 
investigator-assessed histology was leiomyosarcoma in 
approximately two-thirds of patients and liposarcoma in 
the remaining third of patients. The most common pri-
mary site of disease was retroperitoneal (23% of patients), 
uterus (22%), lower extremity (21%), and other abdomen 
and pelvic sites (18%). Patients were randomized 1:1 to 
receive trabectedin in two dosage schedules: 1.5 mg/m2 
administered as a 24-h infusion once every 3 weeks or 
0.58 mg/m2 administered as a 3-h infusion weekly for 3 
weeks out of every four (18). Trabectedin 1.5 mg/m2 every 
3 weeks was associated with a significantly greater TTP 
compared with trabectedin 0.58 mg/m2 weekly (3.7 vs. 2.3 
months; p = 0.03) (Table 1) (18). The median TTP was also 
significantly greater with three-weekly trabectedin com-
pared with weekly dosing when investigator-reported data 
were examined (4.2 vs. 2.5 months; p = 0.005). A greater 
proportion of patients receiving three-weekly trabect-
edin compared with those receiving weekly dosing were 
 progression-free at 3 (52% vs. 45%) and 6 (36% vs. 28%) 
months (Table 1) (18). Moreover, the median OS was 13.9 
and 11.8 months in the respective groups. Over three times 
as many patients receiving three-weekly trabectedin expe-
rienced an objective response than those receiving weekly 
dosing (5.6% vs. 1.6%) (18).Two pooled analyses of phase 
II studies have examined the effect of age on the efficacy 
of trabectedin as second-line treatment of sarcoma and in 
the treatment of translocation-related sarcoma (19,20). 
Demetri et al. showed that the efficacy of trabectedin 1.5 mg/ 
m2 every 3 weeks was not affected by patient age in their 
pooled analysis of five studies (21). Older patients (n = 83; 
median age = 65 years, range = 60−81 years) and patients 
aged <60 years (n = 267; median age = 48 years) both 
experienced an ORR of 10%, with stable disease achieved 
in 47% and 40% of patients, respectively. PFS at 6 months 
was seen in 36% of elderly patients and 30% of younger 
patients; survival rates in elderly patients and younger 
patients were similar at 1 year (56% and 55%) and 2 years 
(38% and 29%) (21).
Approximately a quarter of sarcomas involves a chro-
mosomal translocation (20) and a pooled analysis of 
data from 82 patients in eight studies showed that tra-
bectedin was effective in this patient group (22). A partial 
Table 1. Efficacy of Intravenous Trabectedin in the Treatment of Advanced or Metastatic Liposarcoma or Leiomyosarcoma After 
Failure of Prior Anthracycline- and Ifosfamide-Based Chemotherapy in a Randomized, Open-Label Phase II Study (18)
Statistical Analysis
Arm A Arm B HR (95% CI) p Value
Trabectedin dose 1.5 mg/m2 q3w 0.58 mg/m2 q1w 3/4 weeks
Administration 24-h infusion 3-h infusion
No. of patients 136 134
Median no. of cycles 5 2
Median TTP (independent review;
 primary endpoint) (mo)
3.7 2.3 0.734 (0.554, 0.974) 0.032
Median TTP (investigator review) (mo) 4.2 2.5 0.668 (0.506, 0.883) 0.0046
Median PFS (mo) 3.3 2.3 0.755 (0.574, 0.992) 0.0418
Median OS (mo) 13.9 11.8 0.843 (0.653, 1.090) 0.192
ORR (%) 5.6 1.6
CI, confidence interval; HR, hazard ratio; mo, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; qxw, every 
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response was seen in 10% of patients and stable disease 
in 49% of patients. The median PFS was 4.1 months, and 
the median OS was 17.4 months. Eighty-one patients 
included in this analysis had received previous chemo-
therapy for sarcoma, and one patient was chemotherapy-
naive (22). A phase III study of trabectedin compared 
with a doxorubicin-based chemotherapy regimen as first-
line therapy in translocation-related sarcoma is ongoing 
(NCT00796120-clinicaltrials.gov).
Trabectedin was effective in the treatment of advanced, 
recurrent myxoid liposarcoma, as assessed by study 
investigators, according to the results of a retrospective 
analysis of a trabectedin compassionate use program 
(23). Trabectedin was administered at doses of 1.1− 
1.5 mg/m2 administered over 3 or 24 h every 3 weeks. 
Of the 51 patients who received trabectedin, two achieved 
a complete response and 24 achieved partial response, 
making an ORR of 51%. At 6 months, 88% of patients 
were progression free, and the median PFS was 14.0 
months (23).
In addition to the phase III first-line study described 
above, trabectedin is currently being compared with dac-
arbazine for the treatment of advanced liposarcoma or 
leiomyosarcoma previously treated with anthracycline 
and ifosfamide in an American registration phase III trial 
(SAR 3007; NCT01343277). This study, and a number 
of phase II studies, should further define the place of tra-
bectedin in the treatment of soft-tissue sarcoma.
Clinical Studies as Neoadjuvant Therapy
Preliminary results from a small phase II study sug-
gested that trabectedin might be effective as neoadjuvant 
treatment of locally advanced (stage III) or recurrent, 
nonmetastatic, measurable myxoid/round cell liposar-
coma (9). Using RECIST criteria, 5 of 19 (26%) patients 
achieved a partial response and 14 (74%) achieved stable 
disease. Patients received trabectedin 1.5 mg/m2 admin-
istered over 24 h every 3 weeks for three to six cycles 
prior to surgery (9). Data were included from 29 patients 
of which 19 received a complete course of trabectedin, 
underwent surgery, and were evaluable for RECIST 
response. Patients had not previously received chemo-
therapy or radiotherapy except for adjuvant postopera-
tive radiotherapy (9). On these bases, the Italian Sarcoma 
Group has decided to launch a new prospective controlled 
randomized trial in patients with high-risk soft tissue 
sarcomas, comparing standard full-dose anthracycline + 
ifosfamide versus histotype tailored chemotherapy in 
five definite histotypes. [The selected histotype and the 
respective tailored systemic therapy are as follows: leio-
myosarcoma – gemcitabine + dacarbazine; myxoid-round 
cell liposarcoma (cellular component > 5%) – trabectedin; 
synovial sarcoma – high dose continuous infusion ifos-
famide; malignant peripheral nerve sheath tumor – 
ifosfamide + etoposide; undifferentiated pleomorphic 
sarcoma – gemcitabine + docetaxel.]
Tolerability of Trabectedin 
Grade 3/4 hematological adverse events occurring 
in the phase II study in patients with advanced or meta-
static liposarcoma or leiomyosarcoma were neutropenia, 
thrombocytopenia, and anemia, which occurred in 47%, 
11%, and 8% of patients receiving trabectedin 1.5 mg/
m2 three-weekly and 14%, 6%, and 9% of those receiv-
ing trabectedin 0.58 mg/m2 (Fig. 2) (18). Neutropenia and 
thrombocytopenia of grade 3 or 4 were generally tran-
sient, persisting for 5–7 days, and resolving quickly. The 
incidence of febrile neutropenia was very low, occurring 
in <1% of patients in each treatment arm (18).
The most frequently occurring biochemical abnor-
malities in patients receiving trabectedin were elevations 
in liver function tests (Fig. 2) (18). Grade 3/4 increases 
in ALT and AST occurred in 47% and 32% of patients 
receiving three-weekly trabectedin and 9% and 3% of 
those receiving weekly dosing. ALT and AST remained 
elevated for a median of 5−7 days and subsequent seri-
ous hepatic complications, such as jaundice and hepatic 
failure occurred in <1% of patients (18). Grade 3/4 
elevations in creatine phosphokinase occurred in 5% of 
patients receiving trabectedin 1.5 mg/m2 every 3 weeks 
and in 10% of those receiving weekly dosing.
Rhabdomyolysis is a very rare toxic event, with an 
overall incidence of 0.7% as shown in a recent large analy-
sis (10,841 patients: 2,789 from clinical trials; 3,926 from 
compassionate use programs; and 4,126 treated in the mar-
ketplace) (24). No predictive factors for this event were 
disclosed. Despite its low frequency, a routing monitoring 
of the creatine kinase level remains advisable (24,25). In 
order to reduce the potential for trabectedin-induced hepa-
totoxicity and myelosuppression, dexamethasone premedi-
cation is necessary, starting from the day before trabectedin 
administration (26). A recent analysis of trabectedin-related 
cardiac adverse events retrieved from clinical trials, phar-
macovigilance databases and spontaneously reported case 
revealed a low incidence, consisting mainly of arrhyth-
mias, indicating that trabectedin has a low cardiac risk pro-
file. The incidence of all grades of cardiac adverse events 
in a total of 1,132 patients treated with trabectedin weekly, 
every 3 weeks or every 4 weeks, was <1% (27).
Subjective treatment-related adverse events included 
gastrointestinal effects and fatigue (18). Grade 3/4 fatigue, 
abdominal pain, nausea, and vomiting occurred in 8%, 
5%, 5%, and 5% of patients receiving trabectedin 1.5 mg/
m2 every 3 weeks and 7%, 5%, 2% and 2% of patients 
receiving weekly dosing. Other adverse events often 
seen with other chemotherapy agents, such as alopecia, 
























































6 GALIZIA ET AL.
Figure 2. Incidence of (A) grade 1/2 treatment-related adverse events occurring in ≥20% of patients and (B) grade 3/4 treatment-
related adverse events occurring in ≥5% of patients receiving intravenous trabectedin in a randomized, open-label phase II study (18). 
Patients had advanced or metastatic liposarcoma or leiomyosarcoma, had failed prior anthracycline- and ifosfamide-based chemo-
therapy, and received trabectedin 1.5 mg/m2 over 24 h every 3 weeks or 0.58 mg/m2 over 3 h weekly for 3 weeks of four. ALP, alkaline 
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DISCUSSION
Just as there is some evidence suggesting that differ-
ent histological subtypes of soft tissue sarcoma respond 
differently to chemotherapy, it is also reasonable to 
assume that leiomyosarcoma represents a spectrum of 
diseases with different sensitivities to chemotherapy (5). 
Leiomyosarcoma of nonvisceral soft tissue has not been 
well characterized; however, it is known that, in the pres-
ence of distant metastasis, either at the time of the diag-
nosis or afterwards, this disease is associated with a very 
poor prognosis, with a 5-year survival rate of 16% (3). 
Trabectedin has not been selectively studied in patients 
with leiomyosarcoma of non-visceral soft tissue. In 
the clinical trial by Demetri et al., the wide majority of 
treated leiomyosarcomas originated from uterus, retro-
peritoneum and other abdomen or pelvic sites (18). Our 
case specifically helps to clarify the utility of trabectedin 
in the treatment of patients with primary leiomyosarcoma 
of the nonvisceral soft tissue, in this case the thigh, which 
has metastasized and progressed after therapy with stan-
dard treatment options.
It is accepted practice that, in patients with leiomyo-
sarcoma who maintain reasonable performance status, 
trabectedin may be standard option after the use of anthra-
cycline based chemotherapy (4). Accordingly, our patient 
began second-line therapy with trabectedin after leiomyo-
sarcoma of the thigh metastasized to the lung after surgery 
and adjuvant anthracycline-based chemotherapy and after 
progression of lung metastases, following therapy with 
gemcitabine. During 17 months of well tolerated treatment 
with trabectedin, our patient displayed consistently stable 
disease on chest CT scan, with no respiratory symptoms. 
As was the case with our patient, trabectedin is generally 
well tolerated in heavily pretreated patient populations, 
which, in conjunction with a lack of cumulative toxicity, 
allows patients who benefit from treatment to continue for 
a prolonged number of treatment cycles (16,17). Nausea 
and vomiting are generally not serious with trabectedin, 
and fatigue is often the main subjective adverse event 
(25). Indeed, grade 2 fatigue was our patient’s most severe 
complaint. Myelosuppression is the limiting toxicity of 
trabectedin (25), but despite grades 3 and 4 neutropenia 
and thrombocytopenia during anthracycline-based che-
motherapy, our patient did not experience neutropenia or 
thrombocytopenia during therapy with trabectedin. 
In conclusion, we reported the case of a heavily pre-
treated 76-year-old patient with metastatic leiomyosar-
coma of the thigh and moderate renal failure, who achieved 
17 months of disease stability during second-line trabecte-
din treatment. To our knowledge, this is the first report docu-
menting an effective treatment with trabectedin in a patient 
with renal failure. Despite this concomitant condition and 
a number of important comorbidities, including type 2 
diabetes and hypertension, our patient did not experience 
any major toxicity during 22 cycles of trabectedin therapy. 
For our patient with progressive metastatic lung disease, 
prolonged disease stabilization was a meaningful outcome, 
and trabectedin was instrumental in helping us to achieve 
our goals of care, which were to halt disease progression, 
while maintaining quality of life. 
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